Funding

Dimension Therapeutics raises $65M in Series B

20 Views

What does Dimension Therapeutics do?

Dimension Therapeutics, is a gene therapy company which develops novel treatment for rare diseases. Its team consists of biotech industry veterans and thought leaders in gene therapy and rare diseases. The startup focuses on expanding its platform for gene therapy programs in rare diseases via clinical development, beginning with lead programs in hemophilia and constructing a world class product engine for the AAV- adeno associated virus therapeutics. In association with its launch, Dimension Therapeutics has collaborates and entered into an exclusive license with REGENX Biosciences. Through its collaboration and license with REGENX, Dimension has accomplished elected access to NAV vector technology and rights within REGENX product programs in many rare disease indications.

How much Dimension Therapeutics was funded?

Dimension Therapeutics raised $65M in Series B financing on April 21st, 2015 from OrbiMed, Rock Springs Capital, Fidelity Biosciences, Partner Fund Management (PFM), RA Capital Management and Jennison Associates.

Previous funding

  • $5M in Venture funding on November 18, 2013
  • $30M in Series A funding on June 23, 2014 from OrbiMed Advisors, Fidelity Biosciences
  • $24.5M in Private Equity funding on February 12, 2015

What is next for Dimension Therapeutics?

Dimension Therapeutics’s latest funding will be used to  further advance the company’s adeno-associated associated virus platform and growing gene therapy programs pipeline. The startup’s first program is expected to enter clinical testing with Hemophilia B patients in the second half of 2015. Other programs to treat rare diseases are expected to enter the IND enabling studies during the next twelve to eighteen months.

More about Dimension Therapeutics

Dimension Therapeutics was founded in 2013 by Ben Auspitz. It is focused on developing novel treatment for the devastating disorders which are associated with the liver and based on the AAV platform. Dimension Therapeutics is advancing many programs towards clinical development. Its team and senior advisors include veterans of biotech industry and renowned leaders in rare diseases and gene therapy.

 

Related Posts